SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
SKBI was delisted on the 18th of December, 2015.
6 hedge funds and large institutions have $672K invested in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in 2013 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
20% more funds holding
Funds holding: 5 → 6 (+1)
15% less capital invested
Capital invested by funds: $795K → $672K (-$123K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$420K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$118K |
| 3 |
N
Natixis
Paris,
France
|
+$70.7K |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$9.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Corsair Capital Management
New York
|
-$358K |
| 2 |
Mitsubishi UFJ Asset Management
Tokyo,
Japan
|
-$87K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$36K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BIT
1
BlackRock Institutional Trust
San Francisco,
California
| $334K | +$420K | +95,253 | New |
|
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $125K | -$36K | -8,169 | -19% |
|
|
VKH
3
Virtu KCG Holdings
New York
| $94K | +$118K | +26,821 | New |
|
4
California Public Employees Retirement System
Sacramento,
California
| $56K | – | – | – |
|
|
N
5
Natixis
Paris,
France
| $56K | +$70.7K | +16,012 | New |
|
|
U
6
UBS
Zurich,
Switzerland
| $7K | +$9.14K | +2,072 | New |
|
|
CCM
7
Corsair Capital Management
New York
| – | -$358K | -61,258 | Closed |
|
|
8
Mitsubishi UFJ Asset Management
Tokyo,
Japan
| – | -$87K | -15,000 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$3K | -454 | Closed |
|
SKBI Hedge Fund Activity: Q4 2013 in Review
6 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) for Q4 2013, worth a combined $672K — down 15% from $795K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SKBI positions and 3 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was BlackRock Institutional Trust, opening a new position worth an estimated $420K. The largest seller was Corsair Capital Management, exiting entirely with an estimated $358K sold.
- 6 institutional investors held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) as of Q4 2013, up from 5 in Q3 2013.
- Funds reported $672K of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) stock for Q4 2013, down 15% quarter-over-quarter.
- 4 funds opened new SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) positions in Q4 2013 and 3 closed out, a net change of +1 holder.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) buyer in Q4 2013 was BlackRock Institutional Trust, an estimated $420K added.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) seller in Q4 2013 was Corsair Capital Management, an estimated $358K sold.
Based on aggregated 13F filings for Q4 2013.